ACTIV-4 trials to zero in on best agents and disease stages for addressing blood clots in COVID-19

NIH’s trio of adaptive ACTIV-4 Antithrombotics studies are going beyond identifying which drugs most effectively prevent blood clots in individuals infected with SARS-CoV-2 to figuring out when in the course of COVID-19 the drugs will be beneficial.

The National Heart, Lung and Blood Institute (NHLBI) announced Thursday the launch of the first two Phase III studies to prevent blood clots in COVID-19 patients: the open-label ACTIV-4-Antithrombotics Inpatient trial and the double-blind ACTIV-4-Antithrombotics Outpatient trial. ...